The role of metabolites of antidepressants in the treatment of depression

CNS Drugs

Volumn 7, Issue 4, 1997, Pages 273-312

  Rudorfer, Matthew V ^a   Potter, William Z ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

DEPRESSION; DRUG METABOLISM; HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0030949753     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199707040-00003     Document Type: Review

References (275)

1. Rudorfer MV, Linnoila M, Potter WZ. Accidental antidepressants: search for specific action. In: Dahl SG, Gram LF, Paul SM, et al., editors. Clinical pharmacology in psychiatry. IV. Selectivity in psychotropic drug action: promises or problems? Heidelberg: Springer-Verlag, 1987: 157-66
2. Rudorfer MV, Potter WZ. Pharmacokinetics of antidepressants. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 1353-63
3. Hammer W, Sjöqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci 1967; 6: 1895-903
4. Potter WZ, Calil HM, Sutfin T, et al. Active metabolites of imipramine and desipramine in man. Clin Pharmacol Ther 1982; 31: 393-401
5. Caccia S, Garattini S. Pharmacokinetic and pharmacodynamic significance of antidepressant drug metabolites. Pharmacol Res 1992; 26: 317-29
6. Rudorfer MV, Potter WZ. Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs. Drugs 1989; 37: 713-38
7. Potter WZ, Manji HK. Antidepressants, metabolites, and apparent drug resistance. Clin Neuropharmacol 1990; 13 Suppl. 1: S45-53
8. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994; 10: 18-46
9. Potter WZ, Rudorfer MV, Manji HK. The pharmacologic treatment of depression. N Engl J Med 1991; 325: 633-42
10. Potter WZ, Manji HK, Rudorfer MV. Tricyclics and tetracyclics. In: Schatzberg AF, Nemeroff CB, editors. The American Psychiatric Press textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995: 141-60
11. Watkins PB. Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 1990; 10: 235-50
12. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol 1996; 16: 273-85
13. Shen WW, Lin K-M. Cytochrome P450 monooxygenases and interactions of psychotropic drugs. Int J Psychiatry Med 1991; 21: 47-56
14. Shen WW. Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Int J Psychiatry Med 1995; 25: 271-84
15. Rudorfer MV, Lane EA, Chang W-H, et al. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 1984; 17: 433-40
16. Träskman L, Åsberg M, Bertilsson L, et al. Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression. Clin Pharmacol Ther 1979; 26: 600-10
17. Linnoila M, Insel T, Kilts C, et al. Plasma steady-state concentrations of hydroxylated metabolites of clomipramine. Clin Pharmacol Ther 1982; 32: 208-11
18. Balant-Gorgia AE, Gex-Fabry M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin Pharmacokinet 1991; 20: 447-62
19. Shmioda K, Noguchi T, Ozeki Y, et al. Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation, and glucuronidation. Neurospychopharmacology 1995; 12: 323-33
20. Young RC, Dhar AK, Kutt H, et al. Isomers of 10-hydroxynortriptyline in geriatric depression. Ther Drug Monit 1988; 10: 164-7
21. Nordin C, Bertilsson L. Active hydroxymetabolites of antidepressants: emphasis on E-10-hydroxy-nortriptyline. Clin Pharmacokinet 1995; 28: 26-40
22. Shimoda K, Noguchi T, Morita S, et al. Interindividual variations of desmethylation and hydroxylation of amitriptyline in a Japanese psychiatric population. J Clin Psychopharmacol 1995; 15: 175-81
23. Lancaster SG, Gonzalez JP. Dothiepin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1989; 38: 123-47
24. Alvan G, Borga O, Lind M, et al. Concentrations of parent drug and major metabolites in plasma. Eur J Clin Pharmacol 1977; 11: 219-24
25. Mellström B, Alvan G, Bertilsson L, et al. Nortriptyline formation after single oral and intramuscular doses of amitriptyline. Clin Pharmacol Ther 1982; 32: 664-7
26. Golden RN, Gilmore JH, Carson SW. Antidepressant challenge tests: the interface of pharmacokinetics and pharmacodynamics. Psychopharmacol Bull 1991; 27: 611-7
27. Duhl-Puustinen M-L, Åberg-Wistedt A, Bertilsson L. Glucuronidation of amitriptyline in man in vivo. Toxicology 1989; 65: 37-9
28. Ziegler VE, Fuller TA, Biggs JT. Nortriptyline and 10-hydroxynortriptyline plasma concentrations. J Pharm Pharmacol 1976; 28: 849-50
29. Bertilsson L, Mellström B, Sjöqvist F. Pronounced inhibition of noradrenaline uptake by 10-hydroxy-metabolites of nortriplyline. Life Sci 1979; 25: 1285-92
30. Bock J, Giller E, Gray S, et al. Steady-state plasma concentrations of cis- and trans-10-OH amitriptyline metabolites. Clin Pharmacol Ther 1982; 31: 609-16
31. Young RC, Alexopoulos GS, Shamoian CA, et al. Plasma 10-hydroxynortriptyline in elderly depressed patients. Clin Pharmacol Ther 1984; 35: 540-4
32. Nordin C, Bertilsson L, Siwers B. CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite. Br J Pharmacol 1985; 20: 411-3
33. Edelbroek PM, Zitman FG, Knoppert-van der Klein EAM, et al. Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women. Clin Chim Acta 1987; 165: 177-87
34. Bertilsson L, Nordin C, Otani K, et al. Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects. Clin Pharmacol Ther 1986; 40: 261-7
35. Bertilsson L, Dahl-Puustinen M-L, Nordin C. E-10-hydroxynortriptyline: effects and disposition of a potential novel antidepressant. In: Dahl SG, Gram LF, editors. Clinical pharmacology in psychiatry. Berlin: Springer-Verlag, 1989: 52-9
36. Dahl-Puustinen M-L, Perry TL, Dumont E, et al. Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. Clin Pharmacol Ther 1989; 45: 650-6
37. Nordin C, Bertilsson L, Dahl-Puustinen M-L, et al. Treatment of depression with E-10-hydroxynortriptyline: a pilot study on biochemical effects and pharmacokinetics. Psychopharmacology 1991; 103: 287-90
38. Potter WZ, Calil HM, Zavadil AP, et al. Steady-state concentrations of hydroxylated metabolites of tricyclic antidepressants in patients: relationship to clinical effect. Psychopharmacol Bull 1980; 16: 32-4
39. Wilens TE, Biederman J, Baldessarini RJ, et al. Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. J Am Acad Child Adolesc Psychiatry 1992; 31: 691-8
40. Gram LF, Bjerre M, Kragh-Sørensen P, et al. Imipramine metabolites in blood of patients during therapy and after overdose. Clin Pharmacol Ther 1983; 33: 335-42
41. Brosen K, Gram LF, Klysner R, et al. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics. Eur J Pharmacol 1986; 30: 43-9
42. Sutfin T, Perini G, Molnar G, et al. Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. J Clin Psychopharmacol 1988; 8: 48-53
43. Cooke RG, Warsh JJ, Stancer HC, et al. The nonlinear kinetics of desipramine and 2-hydroxydesipraminc in plasma. Clin Pharmacol Ther 1984; 36: 343-9
44. Preskorn S, Irwin H. Toxicity of tricyclic antidepressants: kinetics, mechanism, intervention. A review. J Clin Psychiatry 1982; 43: 151-6
45. Jarvis MR. Clinical pharmacokinetics of tricyclic antidepressant overdose. Psychopharmacol Bull 1991; 27: 541-50
46. Nelson JC, Mazure C, Jatlow PI. Clinical implications of the pharmacokinetics of tricyclic antidepressant. In: Dahl SG, Gram LF, editors. Clinical pharmacology in psychiatry. Berlin: Springer-Verlag, 1989: 219-27
47. DeVane CL, Jusko W. Plasma concentration monitoring of hydroxylated metabolites of imipramine and desipramine. Drug Intell Clin Pharm 1981; 15: 263-6
48. Pollock BG, Perel JM. Hydroxy metabolites of tricyclic antidepressants: evaluation of relative cardiotoxicity. In: Dahl SG, Gram LF, editors. Clinical pharmacology in psychiatry. Berlin: Springer-Verlag, 1989: 232-6
49. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harv Rev Psychiatry 1994; 2: 204-13
50. Neilsen KK, Gram LF. Steady-state plasma levels of clomipramine and its metabolites: impact of sparteine/debrisoquine oxidation polymorphism. Eur J Pharmacol 1992; 43: 405-11
51. Balant-Gorgia AE, Balant LP, Genet C, et al. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 1986; 31: 449-55
52. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42
53. Rudorfer MV, Golden RN, Potter WZ. Second-generation antidepressants. Psychiatr Clin North Am 1984; 7: 519-34
54. Rudorfer MV. Pharmacokinetics of psychotropic drugs in special populations. J Clin Psychiatry 1993; 54 Suppl. 9: 50-4
55. Lin K-M, Poland RE. Ethnicity, culture, and psychopharmacology. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press Ltd., 1995: 1907-17
56. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994; 55 Suppl. 12: 38-45
57. Skjelbo E, Brosen K, Hallas J, et al. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991; 49: 18-23
58. Breyer-Pfaff U, Pfandl B, Nill K, et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992; 52: 350-8
59. Koyama E, Tanaka T, Chiba K, et al. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4′-hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol 1996; 16: 286-93
60. Mellström B, Bertilsson L, Säwe J, et al. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxlylation. Clin Pharmacol Ther 1981; 30: 189-93
61. Jefferson JW. Tamoxifen-associated reduction in tricyclic antidepressant levels in blood. J Clin Psychopharmacol 1995; 15: 223-4
62. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995; 15: 387-98
63. Spina E, Pollicino AM, Avenoso A, et al. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res 1993; 13: 167-71
64. Spina E, Pollicino AM, Avenoso A, et al. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993; 15: 243-6
65. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993; 54 Suppl. 9: 14-34
66. Sjöqvist F. Pharmacogenetics of antidepressants. In: Dahl SG, Gram LF, editors. Clinical pharmacology in psychiatry. Berlin: Springer-Verlag, 1989: 181-91
67. Bertilsson L, Åberg-Wistedt A, Gustafsson LL, et al. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985; 7: 478-80
68. Bertilsson L, Dahl M-L, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [letter]. Lancet 1993; 341: 63
69. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-9
70. Bertilsson L, Dahl M-L. Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200-23
71. Pollock BG, Perel JM, Altieri L, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992; 28: 163-8
72. Foglia JP, Pollock BG, Kirshner M, et al. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 1997; 33: 109-12
73. Dawkins K, Potter WZ. Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: focus on women. Psychopharmacol Bull 1991; 27: 417-26
74. Gex-Fabry M, Balant-Gorgia AE, Balant LP, et al. Clomipramine metabolism: model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet 1990; 19: 241-55
75. Nordin C. CSF/plasma ratio of 10-hydroxynortriptyline is influenced by sex and body height. Psychopharmacology 1993; 113: 222-4
76. Ben Musa A, Smith CS. Neonatal effects of maternal clomipramine therapy [abstract]. Arch Dis Child 1979; 54: 405
77. Schimmell MS, Katz EZ, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. Clin Toxicol 1991; 29: 479-84
78. Rudorfer MV. Challenges in medication clinical trials. Psychopharmacol Bull 1993; 29: 35-44
79. Vitiello B, Jensen PS. Developmental perspectives in pediatric psychopharmacology. Psychopharmacol Bull 1995; 31: 75-81
80. Young RC. Hydroxylated metabolites of antidepressants. Psychopharmacol Bull 1991; 27: 521-32
81. Wisner KL, Perel JM, Foglia JP. Serum clomipramine and metabolite levels in four nursing mother-infant pairs. J Clin Psychiatry 1995; 56: 17-20
82. Wisner KL, Perel JM. Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry 1991; 148: 1234-6
83. Brixen-Rasmussen L, Halgrener J, Jorgensen A. Amitriptyline and nortriptyline excretion in human breast milk. Psychopharmacology 1982; 76: 94-5
84. Breyer-Pfaff U, Entenmann A, Gaertner HJ. Secretion of amitriptyline and metabolites into breast milk. Am J Psychiatry 1995; 152: 812-3
85. Matheson J, Pande H, Alersten AR. Respiratory depression caused by N-desmethyldoxepin in breast milk [letter]. Lancet 1985; 2: 1124
86. Kemp J, Ilett KF, Booth J. Excretion of doxepin and N-desmethyldoxepin in human milk. Br J Clin Pharmacol 1985; 20: 479-84
87. Buist A, Janson H. Effect of exposure to dothiepin and northiaden in breast milk on child development. Br J Psychiatry 1995; 167: 370-3
88. Shoaf SE, Linnoila M. Interaction of ethanol and smoking on the pharmacokinetics and pharmacodynamics of psychotropic medications. Psychopharmacol Bull 1991; 27: 577-94
89. Spina E, Perucca E. Newer and older antidepressants: a comparative review of drug interactions. CNS Drugs 1994; 2: 479-97
90. Fleischmann R, Remmer H, Starz U. Induction of cytochrome P-448 iso-enzymes and related glucuronyltransferases in the human liver by cigarette smoking. Eur J Clin Pharmacol 1986; 30: 475-80
91. Mellström B, Säwe J, Bertilsson L, et al. Amitriptyline metabolism: association with debrisoquine hydroxylation in non-smokers. Clin Pharmacol Ther 1986; 39: 369-71
92. Perry PJ, Browne JL, Prince RA, et al. Effects of smoking on nortriptyline plasma concentrations in depressed patients. Ther Drug Monit 1986; 8: 279-84
93. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo (OK): Professional Communications, Inc., 1996
94. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994; 14: 90-8
95. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992; 51: 239-48
96. Geller B, Cooper TB, Graham DL, et al. Pharmacokinetically designed, double-blind, placebo-controlled study of nortriptyline in 6-to-12-year olds with major depressive disorder. J Am Acad Child Adolesc Psychiatry 1992; 31: 34-44
97. Hazell P, O'Connell D, Heathcote D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995; 310: 897-901
98. Geller B. Psychopharmacology of children and adolescents: pharmacokinetics and relationships of plasma/serum levels to response. Psychopharmacol Bull 1991; 27: 401-9
99. Preskorn SH, Bupp SJ, Weller EB, et al. Plasma levels of imipramine and metabolites in 68 hospitalized children. J Am Acad Child Adolesc Psychiatry 1989; 28: 373-5
100. Donnelly M, Zametkin AJ, Rapoport JL, et al. Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther 1986; 39: 72-81
101. Lane EA. Renal function and the disposition of antidepressants and their metabolites. Psychopharmacol Bull 1941; 27: 533-40
102. Kitanaka I, Ross RJ, Cutler NR, et al. Altered hydroxydesipramine concentrations in elderly depressed patients. Clin Pharmacol Ther 1982; 31: 51-5
103. Nelson JC, Atillasoy E, Mazure C, et al. Hydroxydesipramine in the elderly. J Clin Psychopharmacol 1988; 8: 428-33
104. Young KC, Alexopoulos GS, Dhar AK, et al. 10-hydroxynortriptylirie and renal function in elderly depressives. Biol Psychiatry 1987; 22: 1283-7
105. Schneider LS, Cooper TB, Suckow RF, et al. Relationship of hydroxynortriptyline to nortriptyline concentration and creatinine clearance in depressed elderly outpatients. J Clin Psychopharmacol 1990; 10: 333-7
106. Asberg M, Cronholm B, Sjöqvist F, et al. Relationship between plasma levels and therapeutic effect of nortriptyline. BMJ 1971; 3: 331-4
107. Ng Ying Kin NMK, Klitgaard N, Nair NPV, et al. Clinical relevance of serum nortriptyline and 10-hydroxy-nortriptyline measurements in the depressed elderly: a multicenter pharmacokinetic and pharmacodynamic study. Neuropsychopharmacology 1996; 15: 1-6
108. Dawling S, Lynn K, Rosser R, et al. Nortriptyline metabolism in chronic renal failure: metabolite elimination. Clin Pharmacol Ther 1982; 32: 322-9
109. Lieberman JA, Cooper TB, Suckow RE, et al. Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 1985; 37: 301-7
110. Potter WZ, Lane LA, Rudorfer MV. Hydroxy metabolite concentrations: role of renal clearance. In: Gram LE, Usdin E, Dahl SG, et al. editors. Clinical pharmacology in psychiatry: bridging the experimental-therapeutic gap. London: Macmillan Press, 1983: 203-16
111. Potter WZ, Calil HM, Manian A, et al. Hydroxylated metabolites of tricyclic antidepressants. Biol Psychiatry 1979; 14: 601-13
112. Javaid JI, Perd JM, Davis JM. Inhibition of biogenic amine uptake by imipramine, desipramine, 2 OH-imipramine and 2 OH-desipramme in rat brain. Life Sci 1979; 24: 21-8
113. Potter WZ, Rudorfer MV, Lane EA. Active metabolites of antidepressants: pharmacodynamics and relevant pharmacokinetics. In: Usdin E, Bertilsson L, Sjöqvist F, editors. Frontiers in biochemical and pharmacological research in depression. New York: Raven Press, 1984: 373-90
114. Nunez R, Perel JM. Comparative neurotransmitter reuptake and anticholinergic potencies of the 8-hydroxy metabolites of clomipramine. Psychopharmacol Bull 1995; 31: 217-21
115. Potter WZ, Calil HM. Metabolites of tricyclic antidepressants: biological activity and clinical implicalions. In: Usdin E, editor. Clinical pharmacology in psychiatry. New York: Elsevier North Holland Inc., 1981: 311-24
116. Potter WZ, Rudorfer MV, Linnoila M. New clinical studies support a role of norepinephrine in antidepressant action. In: Barchas JD, Bunney Jr WE, editors. Perspectives in psychopharmacology: a collection of papers in honor of Earl Usdin. New York: Alan R. Liss Inc., 1988: 495-513
117. Nordin C, Bertilsson L, Siwers B. Clinical and biochemical effects during treatment with nortriptyline: the role of 10-hydroxynortriptyline. Clin Pharmacol Ther 1987; 42: 10-9
118. Malmgren R, Åberg-Wistedt A, Bertilsson L. Serotonin uptake inhibition during treatment of depression with nortriptyline caused by parent drug and not by 10-hydroxymetabolites. Psychopharmacology 1987; 92: 169-72
119. Snyder SH, Yamamura HI. Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 1977; 34: 236-9
120. Richelson E, Nelson AL. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Toxicol Methods 1984; 230: 94-102
121. Wagner A, Ekqvist B, Bertilsson L, et al. Weak binding of 10-hydroxymetaboliles of nortriptyline to rat brain muscarinic acetylcholine receptors. Life Sci 1984; 35: 1379-83
122. Nilvebrant L, Nordin C. Affinity of nortripiyline and its E-10-hydroxy metabolite for muscarinic receptors. Pharmacol Toxicol 1991; 68: 64-7
123. El-Fakahany E, Richelson E. Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol 1983; 78: 97-102
124. Jandhyala BS, Steenberg ML, Perel JM, et al. Effects of several tricyclic antidepressants on the hemodynamics and myocardial contractility of anesthetized dogs. Eur J Pharmacol 1977; 42: 403-10
125. Wilkerson RD. Antiarrhythmic effects of tricyclic antidepressant drugs in ouabain-induced arrhythmias in the dog. J Pharmacol Exp Ther 1978; 206: 666-74
126. Pollock BG, Everett G, Perel JM. Comparative cardiotoxicity of nortriptyline and its isomeric 10-hydroxymetabolites. Neuropsychopharmacology 1992; 6: 1-10
127. Nierenberg AA, Cole JO. Antidepressant adverse drug reactions. J Clin Psychiatry 1991; 52 Suppl. 6: 40-7
128. Rudorfer MV, Young RC. Anticholinergic effects and plasma desipramine levels. Clin Pharmacol Ther 1980; 28: 703-6
129. Lancaster SG, Gonzalez JP. Lofepramine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1989; 37: 123-40
130. Nordin C, Bertilsson L, Otani K, et al. Little anticholinergic effect of E-10-hydroxynortriptyline compared with nortriptyline in healthy subjects. Clin Pharmacol Ther 1987; 41: 97-102
131. Glassman AH, Roose SP, Bigger Jr JT. The safety of tricyclic antidepressants in cardiac patients: risk-benefit reconsidered. JAMA 1993; 269: 2673-5
132. Rudorfer MV, Young RC. Desipramine: cardiovascular effects and plasma levels. Am J Psychiatry 1980; 137: 984-6
133. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991; 52 Suppl. 6: 23-33
134. Bluhm RE, Wilkinson GR, Shelton R, et al. Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. Clin Pharmacol Ther 1993; 53: 89-95
135. Amitai Y, Erickson T, Kennedy EJ, et al. Tricyclic antidepressants in red cells and plasma: correlation with impaired intraventricular conduction in acute overdose. Clin Pharmacol Ther 1993; 54: 219-27
136. Biederman J, Baldessarini RJ, Goldblatt A, et al. A naturalistic study of 24-hour electrocardiographic recording and echocardiographic findings in children and adolescents treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993; 32: 805-13
137. Wilens TE, Biederman J, Baldessarini RJ, et al. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993; 32: 798-804
138. Nelson JC, Jatlow PI, Bock J. Major adverse reactions during desipramine treatment: relationship to drug plasma concentrations, concomitant antipsychotic treatment and patient characteristics. Arch Gen Psychiatry 1982; 39: 1055-61
139. Cutler NR, Zavadil A, Linnoila M, et al. Effects of chronic desipramine on plasma norepinephrine concentrations and cardiovascular parameters in elderly depressed women: a preliminary report. Biol Psychiatry 1984; 19: 549-56
140. Kutcher SP, Reid K, Dubbin JD, et al. Electrocardiogram changes and therapeutic desipramine and 2-hydroxy-desipramine concentrations in elderly depressives. Br J Psychiatry 1986; 148: 676-9
141. Young RC, Alexopoulos GS, Shamoian CA, et al. Heart failure associated with high plasma 10-hydroxynortriptyline levels. Am J Psychiatry 1984; 141: 432-3
142. Young RC, Alexopoulos GS, Kent E, et al. Plasma 10-hydroxynortriptyline and ECG changes in elderly depressed patients. Am J Psychiatry 1985; 142: 866-8
143. Schneider LS, Cooper TB, Severson JA, et al. Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients. J Clin Psychopharmacol 1988; 8: 402-8
144. McCue RE, Georgotas A, Nagachandran N, et al. Plasma levels of nortriptyline and 10-hydroxynortriptyline and treatment-related electrocardiographic changes in the elderly depressed. J Psychiatr Res 1989; 23: 73-9
145. Calvo B, García MJ, Pedraz JL, et al. Pharmacokinetics of amoxapine and its active metabolites. Int J Clin Pharmacol Ther Toxicol 1985; 23: 180-5
146. Anton Jr RF, Burch Jr EA. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry 1990; 147: 1203-8
147. Gelenberg AJ, Cooper DS, Doller JC, et al. Galactorrhea and hyperprolactinemia associated with amoxapine therapy: report of a case. JAMA 1979; 242: 1900-1
148. Lydiard RB, Gelenberg AJ. Amoxapine: an antidepressant with some neuroleptic properties? Pharmacotherapy 1981; 1: 163-78
149. Huang CC. Persistent tardive dyskinesia associated with amoxapine therapy. Am J Psychiatry 1986; 143: 1069-70
150. Taylor NE, Schwartz HI. Neuroleptic malignant syndrome following amoxapine overdose. J Nerv Ment Dis 1988; 176: 249-51
151. Golden RN, Bebchuk JM, Leatherman ME. Trazodone and other antidepressants. In: Schatzberg AF, Nemeroff CB, editors. The American Psychiatric Press textbook of psychopharmacology. Washington, DC: American Psychiatric Press, Inc., 1995: 195-213
152. Litovitz TL, Troutman WG. Amoxapine overdose. JAMA 1983; 250: 1069-71
153. Cassidy SL, Henry JA. Fatal toxicity of antidepressant drugs in overdose. BMJ 1987; 295: 1021-4
154. Dessain EC, Schatzberg AF, Woods BT, et al. Maprotiline treatment in depression: a perspective on seizures. Arch Gen Psychiatry 1986; 43: 86-90
155. Robinson DS, Cooper TB, Howard D, et al. Amitriptyline and hydroxylated metabolite plasma levels in depressed outpatients. J Clin Psychopharmacol 1985; 5: 83-8
156. Nordin C, Siwers B, Benitez J, et al. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients: relationship to the debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol 1985; 19: 832-5
157. Young RC, Alexopoulos GS, Shindledecker R, et al. Plasma 10-hydroxynortriptyline and therapeutic response in geriatric depression. Neuropsychopharmacology 1988; 1: 213-5
158. Potter WZ, Scheinin M, Golden RN, et al. Selective antidepressants and cerebrospinal fluid: lack of specificity on norepinephrine and serotonin metabolites. Arch Gen Psychiatry 1985; 42: 1171-7
159. Nelson JC, Bock JL, Jatlow P. Clinical implications of 2-hydroxydesipramine plasma concentrations. Clin Pharmacol Ther 1983; 33: 183-9
160. Kutcher SP, Shulman KI, Reed K. Desipramine plasma concentration and therapeutic response in elderly depressives: a naturalistic pilot study. Can J Psychiatry 1986; 31: 752-4
161. Amersterdam JD, Brunswick DJ, Potter WZ, et al. Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients: lack of correlation with therapeutic response. Arch Gen Psychiatry 1985; 42: 361-4
162. Nelson JC, Mazure C, Jatlow PI. Antidepressant activity of 2-hydroxydesipramine. Clin Pharmacol Ther 1988; 88: 283-8
163. Bock JL, Nelson JC, Gray S, et al. Desipramine hydroxylation: variability and effect of antipsychotic drugs. Clin Pharmacol Ther 1983; 33: 322-8
164. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993; 54: 3-15
165. Tollefson GD. Selective serotonin reuptake inhibitors. In: Schatzberg AF, Nemeroff CB, editors. The American Psychiatric Press textbook of psychopharmacology. Washington, DC: American Psychiatric Press Inc., 1995: 161-82
166. Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991; 41: 450-77
167. Palmer KJ, Benfield P. Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs 1994; 1: 57-87
168. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993; 24: 203-20
169. Goodnick PJ. Pharmacokinetics of second generation antidepressants: fluoxetine. Psychopharmacol Bull 1991; 27: 503-12
170. DeVane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992; 53 Suppl. 2: 13-20
171. Wong DT, Bymaster FP, Reid LR, et al. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology 1993; 8: 337-44
172. Torok-Both GA, Baker GB, Coutts RT, et al. Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. J Chromatography 1992; 579: 99-106
173. Pato MT, Murphy DL, DeVane CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 1991; 11: 224-5
174. Coplan JD, Gorman JM. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome [letter]. Am J Psychiatry 1993; 150: 837
175. Feireraband R. Benign course in a child with a massive fluoxetine overdose. J Fam Pract 1995; 41: 289-91
176. Stevens JC, Wrighton SA. Interaction of the enantiomers of fluoxetine with human liver cytochromes P450. J Pharm Exp Ther 1993; 266: 964-71
177. Bergstrom RF, Lemberger L, Faird NA, et al. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988; 153 Suppl. 3: 47-50
178. Schenker S, Bergstrom RF, Wolen RL, et al. Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 1988: 44: 353-9
179. Aronoff GR, Bergstrom RF, Pottratz, ST, et al. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 1984; 36: 138-44
180. Renshaw PF, Guimaraes AR, Fava M, et al. Accumulation of fluoxetine and norfluoxeline in human brain during therapeutic administration. Am J Psychiatry 1992; 149: 1592-4
181. Miner CM, Davidson JRT, Potts NLS, et al. Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. Biol Psychiatry 1995; 38: 696-8
182. Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 1994; 9 Suppl. 3: 13-9
183. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023-9
184. Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307-14
185. Hyttel J, Bogeso KP, Perregaard J, et al. The pharmacological effect of citalopram resides in S(+)-enantiomer. J Neural Transm Gen Sect 1992; 88: 157-60
186. Rochat B, Amey M, Baumann P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit 1995; 17: 273-9
187. Bloomer JC, Woods FR, Haddock RE, et al. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992; 33: 521-3
188. Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 288-95
189. Dechant KL, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991; 41: 225-53
190. Nemeroff CB. The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor. Pharmacotherapy 1994; 14: 127-38
191. Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994; 27: 175-90
192. Spigset O, Carleborg L, Hedenmalm K, et al. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995; 58: 399-403
193. Kelly MW, Perry PJ, Holstad SG, et al. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 1989; 11: 165-70
194. Burke WJ, Hendricks SE, McArthur-Campbell D, et al. Fluoxetine and norfluoxetine serum concentrations und clinical response in weekly versus daily dosing. Psychopharmacol Bull 1996; 32: 27-32
195. Keck Jr PE, McElroy SL. Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. J Clin Psychiatry 1992; 53: 127-9
196. Spencer MJ. Fluoxetine (FLX) neonatal toxicity. Pediatrics 1993; 92: 721-2
197. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995; 15: 417-20
198. Altshuler LL, Burt VK, McMullen M, et al. Breastfeeding and sertraline: a 24-hour analysis. J Clin Psychiatry 1995; 56: 243-5
199. Winn SS, Stowe ZN, Landry JC, et al. Sertraline in breast milk and nursing infants [abstract NR72]. 148th Annual Meeting of the American Psychiatric Association: 1995 May 20-25; Miami
200. Kent LSW, Laidlaw JDD. Suspected congenital sertraline dependence. Br J Psychiatry 1995; 167: 412-3
201. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 311-20
202. Preskorn SH, Janicak PG, Davis JM, et al. Advances in the pharmacotherapy of depressive disorders. In: Janicak PG, editor. Principles and practice of psychopharmacotherapy. Update vol. 1, no. 2. Baltimore: Williams & Wilkins, 1995: 1-24
203. Von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15: 125-31
204. Hartter S, Wetzel H, Hammes E, et al. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology 1993; 110: 301-8
205. Sindrup SH, Brosen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278-87
206. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994; 46: 35-9
207. Holliday SM, Benfield P. Venlataxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49: 280-94
208. Muth EA, Mover JA, Haskins JT, et al. Biochemical, neurophysiological, and behavioral effects of WY-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991; 23: 191-9
209. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993; 23: 349-59
210. Klamerus KJ, Maloney K, Rudolph R, et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992; 32: 716-24
211. Troy SM, Schultz RW, Parker VD, et al. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994; 56: 14-21
212. Taylor DP, Hyslop DK, Riblet A. Trazodone, a new non-tricyclic antidepressant without anticholinergic activity. Biochem Pharmacol 1980; 29: 2149-50
213. Caccia S, Ballabio M, Samanin R, et al. (-)-m-Chlorophenylpiperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone. J Pharm Pharmacol 1981; 33: 477-8
214. Mueller EA, Murphy DL, Sunderlund T. Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology 1986; 89: 388-91
215. Murphy DL, Lesch KP, Aulahk CS, et al. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev 1992; 43: 527-52
216. Seibyl JP, Krystal JH, Price JH, et al. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta chlorophenylpiperazine in healthy human subjects. Psychiatry Res 1991; 38: 227-36
217. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991; 30: 1139-66
218. Charney DS, Woods SW, Goodman WK, et al. Serotonin function in anxiety. Psychopharmacology 1987; 92: 14-24
219. Murphy DL, Mueller EA, Hill JL, et al. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology 1989; 98: 275-82
220. Kalus O, Wetzler S, Kahn RS, et al. A dose-response study of intravenous m-chlorophenylpiperazine in normal subjects. Psychopharmacology 1992; 106: 388-90
221. Stein DJ, Hollander E, Cohen L, et al. Serotonergic responsivity in trichotillomania: neuroendrocrine effects of m-chlorophenylpiperazine. Biol Psychiatry 1995; 37: 414-6
222. Krystal JH, Seibyl JP, Price LH, et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients: evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry 1993; 50: 624-35
223. Krystal JH, Webb E, Cooney NL, et al. Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. Am J Psychiatry 1996; 153: 83-92
224. Anand A, Charney DS, Delgado PL. et al. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry 1994; 151: 1626-30
225. Zohar J, Insel TR, Zohar-Kadouch RC, et al. Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988; 45: 167-72
226. Hollander E, DeCaria C, Gully R, et al. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chloro-phenylpiperazine in obsessive-compulsive disorder. Psychiatry Res 1991; 36: 1-17
227. Pigott TA, Hill JL, Grady TA, et al. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effects of metergoline prior to IV mCPP. Biol Psychiatry 1993; 33: 3-14
228. Barbhaiya RH, Shukla UA, Natarajan CS, et al. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Ther 1995; 58: 390-8
229. Kroboth PD, Folan MM, Lush RM, et al. Coadministration of nefazodone and benzodiazepines. I. Pharmacodynamic assessment. J Clin Psychopharmacol 1995; 15: 306-19
230. Barbhaiya RH, Shukla UA, Kroboth PD, et al. Coadministration of nefazodone and benzodiazepines. II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995; 15: 320-6
231. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines. III. A pharmacokinetic interaction study of alprazolam. J Clin Psychopharmacol 1995; 15: 399-408
232. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines. IV. A pharmacokinetic interaction study with lorazepam. J Clin Psychopharmacol 1995; 15: 409-16
233. Franc JE, Duncan GF, Farmen RH, et al. High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J Chromatogr B Biomed Appl 1991; 570: 129-38
234. Mayol RF, Cole CA, Luke GM, et al. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 1994; 22: 304-11
235. Golden RN, Rudorfer MV, Sherer MA, et al. Bupropion in depression. I. Biochemical effects and clinical response. Arch Gen Psychiatry 1988; 45: 139-43
236. Cooper BR, Wang CM, Cox RF, et al. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 1994; 11: 133-41
237. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401
238. Golden RN, James SP, Sherer MA, et al. Psychoses associated with bupropion treatment. Am J Psychiatry 1985; 142: 1459-62
239. Golden RN. Antidepressant profiles of bupropion and three metabolites: clinical and pre-clinical studies [letter]. Pharmacopsychiatry 1991; 24: 68
240. Laizure SC, DeVane CL, Stewart JT, et al. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther 1985; 38: 586-9
241. Golden RN, DeVane CL, Laizure SC, et al. Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 1988; 45: 145-9
242. DeVane CL, Laizure SC, Stewart JT, et al. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990; 10: 328-32
243. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391-3
244. Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995; 15: 327-33
245. Goodnick PJ. Pharmacokinetics of second generation antidepressants: bupropion. Psychopharmacol Bull 1991; 27: 513-9
246. Golden RN, Markey SP, Risby ED, et al. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiatry 1988; 45: 150-4
247. Nixon AL, Long WH, Puopolo PR, et al. Bupropion metabolites produce false-positive urine amphetamine results. Clin Chem 1995; 41: 955-6
248. Rudorfer MV. Monoamine oxidase inhibitors: reversible and irreversible. Psychopharmacol Bull 1992; 28: 45-57
249. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12: 185-219
250. Mallinger AG, Smith E. Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull 1991; 27: 493-502
251. Baker GB, Coutts RT. Metabolism of monoamine oxidase inhibitors. Neuropsychopharmacology 1989; 13: 395-403
252. Karoum F, Chuang L-W, Eisler T, et al. Metabolism of (-) deprenyl to amphetamine and methamphelamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment. Neurology 1982; 32: 503-9
253. Mallinger AG, Edwards DJ, Himmelhoch JM, et al. Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to cardiovascular effects. Clin Pharmacol Ther 1986; 40: 444-50
254. Mallinger AG, Himmelhoch JM, Thase ME, et al. Plasma tranylcypromine: relationship to pharmacokinetic variables and clinical antidepressant actions. J Clin Psychopharmacol 1990; 10: 176-83
255. Reynolds GP, Rausch WD, Riederer P. Effects of tranylcypromine stereoisomers on monoamine oxidation in man. Br J Clin Pharmacol 1980; 9: 521-3
256. Keck PE, Carter WP, Nierenberg AA, et al. Acute plasma drug metabolite, norepinephrine, and MHPG levels. J Clin Psychiatry 1991; 52: 250-4
257. Youdim MBH, Aronson JK, Blau K, et al. Tranylcypromine (Parnate) overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification. Psychol Med 1979; 9: 377-82
258. Jefferson JW. Is tranylcypromine really metabolized to amphetamine? J Clin Psychiatry 1992; 53: 450-1
259. Brady KT, Lydiard RB, Kellner C. Tranylcypromine abuse. Am J Psychiatry 1991; 148: 1268-9
260. Briggs NC, Jefferson JW, Koenecke FH. Tranylcypromine addiction: a case report and review. J Clin Psychiatry 1990; 51: 426-9
261. Vartzopoulos D, Krull F. Dependence on monoamine oxidase inhibitors in high dose. Br J Psychiatry 1991; 158: 856-7
262. Keek PE, Pope HG, Nierenberg AA. Autoinduction of hypertensive reactions by tranylcypromine? J Clin Psychopharmacol 1989; 9: 48-51
263. Finberg JPM. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A. Acta Psychiatr Scand 1995; 91 Suppl. 386: 8-13
264. Potter WZ, Murphy DL, Wehr TA, et al. Clorgyline: a new treatment for refractory rapid cycling disorder. Arch Gen Psychiatry 1982; 39: 505-10
265. Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994; 51: 607-15
266. Heinonen EH, Anttila MI, Lammintausta RAS. Pharmacokinetic aspects of I-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 1994; 56: 742-9
267. Reynolds GP, Riederer P, Sandler M, et al. Amphetamine and 2-phenylcthylamine in post-mortem Parkinsonian brain after (-)deprcnyl administration. J Neural Transm Park Dis Dement Sect 1978; 43: 271-7
268. Reynolds GP, Blau EK, Sandler M, et al. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 1978; 6: 542-4
269. Schoerlin MP, Mayersohn M, Hoevls B, et al. Cimelidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacol Ther 1991; 49: 32-8
270. Dingemanse J, Kneer J, Fotteler B, et al. Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor. J Clin Psychopharmacol 1995; 15: 41-8
271. Schoerlin MP, Mayersohn M, Korn A, et al. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. Clin Pharmacol Ther 1987; 42: 395-404
272. Fitton A, Faulds D, Goa KL. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992; 43: 561-96
273. Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995; 57: 670-7
274. Pons G, Sehoerlin MP, Tam YK, et al. Moclobemide excretion in human breast milk. Br J Clin Pharmacol 1990; 29: 27-31
275. Schoerlin MP, Horber FF, Frey FJ, et al. Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function. J Clin Pharmacol 1990; 30: 272-84